Welcome to our dedicated page for Cardio Diagnostics Holdings news (Ticker: CDIO), a resource for investors and traders seeking the latest updates and insights on Cardio Diagnostics Holdings stock.
Cardio Diagnostics Holdings Inc (CDIO) delivers AI-powered innovations in cardiovascular risk assessment through its proprietary Genetic-Epigenetic Engine. This dedicated news hub provides investors and healthcare professionals with essential updates on the company's advancements in precision diagnostics.
Access timely announcements about clinical validations, strategic partnerships, and regulatory developments shaping the future of preventive cardiovascular care. Our curated collection includes earnings reports, technology milestones, and peer-reviewed research insights directly impacting CDIO's market position.
Key updates cover advancements in AI-driven diagnostic accuracy, intellectual property expansions, and collaborations with medical institutions. Users gain critical insights into how CDIO's epigenetic analyses are transforming personalized healthcare approaches globally.
Bookmark this page for structured access to verified corporate communications and analysis of CDIO's growing influence in biotechnology. Regularly updated content supports informed tracking of the company's progress in redefining cardiovascular disease prevention through cutting-edge diagnostic solutions.
Cardio Diagnostics Holdings (NASDAQ: CDIO) has announced a 1-for-30 reverse stock split effective May 13, 2025. The split aims to regain compliance with Nasdaq Capital Market's minimum bid price requirement. Following the split, CDIO's outstanding shares will decrease from approximately 52 million to 1.7 million, while authorized shares remain at 300 million.
The reverse split was authorized by stockholders on November 15, 2024, and approved by the Board on April 10, 2025. No fractional shares will be issued, with shares being rounded to the nearest whole number. The company's warrants, stock options, and shares under the 2022 Equity Incentive Plan will be proportionally adjusted to reflect the split ratio.
Cardio Diagnostics Holdings (Nasdaq: CDIO) announced its participation in the American College of Cardiology's 74th Annual Scientific Session (ACC.25) in March 2025. The company will showcase its PrecisionCHD™ test and enhanced Actionable Clinical Intelligence (ACI™) report at Booth #2033.
PrecisionCHD™ is a prescription-based blood test that aids in diagnosing coronary heart disease (CHD) through analyzing 10 genetic and 6 epigenetic markers. The test requires no radiation or fasting and can be performed via standard blood draw or lancet sampling. The enhanced ACI™ report provides clearer insights into patients' modifiable disease drivers, including inflammation-related risk.
The company will present new research demonstrating PrecisionCHD™ methylation biomarkers' ability to predict mortality in Acute Coronary Syndrome (ACS) patients, showing superior predictive capabilities compared to traditional angiographic methods.
Cardio Diagnostics Holdings (Nasdaq: CDIO) has announced partnerships with seven new provider organizations across multiple U.S. regions to expand the reach of its AI-driven cardiovascular tests, Epi+Gen CHD™ and PrecisionCHD™. The new partners include specialized practices in Michigan, Illinois, Texas, Florida, California, and Connecticut, representing various medical specialties including concierge medicine, primary care, and precision medicine.
These partnerships aim to leverage Cardio Diagnostics' advanced genetic and epigenetic testing technology to provide actionable insights into coronary heart disease and heart attack risk, enabling personalized treatment plans. The company's solutions combine epigenetics, genetics, and AI to offer deeper insights into heart disease risk, status, and underlying drivers.
Cardio Diagnostics Holdings (NASDAQ: CDIO) has received final pricing determinations from CMS for its AI-powered cardiovascular tests, PrecisionCHD and Epi+Gen CHD. The decision, effective for claims after January 1, 2025, allows Medicare contractors to determine pricing based on actual cost data, with preliminary gapfill pricing due by April 1, 2025.
Both tests received dedicated CPT PLA codes effective April 1, 2024: 0439U for Epi+Gen CHD and 0440U for PrecisionCHD. PrecisionCHD aids in CHD diagnosis through genetic and epigenetic markers, while Epi+Gen CHD assesses three-year risk for CHD events using an AI-driven integrated genetic-epigenetic approach.
Cardio Diagnostics Holdings (NASDAQ: CDIO) announced its sponsorship and exhibition at the FLAACOs 2024 Annual Fall Conference in Orlando from November 20-22, 2024. The company will showcase its AI-powered cardiovascular solutions at booth #207, demonstrating how they support ACOs in delivering value-based healthcare. CEO Meesha Dogan will participate in a Strategic Innovation panel discussing AI's role in healthcare transformation. The company will also attend the American Heart Association's Scientific Sessions on November 16-18, 2024, in Chicago.
Cardio Diagnostics Holdings, Inc. (NASDAQ: CDIO) has received preliminary pricing determinations from the Centers for Medicare & Medicaid Services (CMS) for its PrecisionCHD and Epi+Gen CHD tests. This marks a important step towards securing Medicare reimbursement for these AI-powered cardiovascular tests. The preliminary 'gapfill' pricing decision, if finalized, will be effective for claims starting January 1, 2025, allowing Medicare contractors to determine pricing based on actual cost data.
The tests aim to improve risk assessment, diagnosis, management, and monitoring of coronary heart disease (CHD) for Medicare patients. PrecisionCHD aids in CHD diagnosis using genetic and epigenetic markers, while Epi+Gen CHD assesses the three-year risk for a CHD event. Both tests received dedicated CPT Proprietary Laboratory Analysis (PLA) codes effective April 1, 2024.
Cardio Diagnostics Holdings Inc. (NASDAQ: CDIO) has launched a redesigned website, CDIO.AI, emphasizing its AI-driven approach to cardiovascular care. The new site highlights three core solutions: Epi+Gen CHD, PrecisionCHD, and the Actionable Clinical Intelligence (ACI) platform. These AI-powered tests assess coronary heart disease risk, detect and manage stable ischemic heart disease, and provide personalized insights for clinicians.
The website enhances user experience for investors, patients, healthcare providers, payers, and researchers. It features streamlined access to financial reports, test information, ordering processes, and collaboration opportunities. The redesign aims to clarify Cardio Diagnostics' position as a leader in precision cardiovascular medicine, showcasing its commitment to improving patient outcomes and reducing healthcare costs through AI-driven diagnostics and prevention strategies.
Cardio Diagnostics announces that its Epi+Gen CHD heart attack risk assessment test is now available at the Family Medicine Specialists' (FMS) retail clinical location within the Meijer Supercenter in McHenry, Illinois. Meijer, a retailer with over 500 locations, primarily serves middle-aged and older adults in the Midwest, a demographic with high heart disease risk. The Epi+Gen CHD test predicts the likelihood of a heart attack or sudden death from coronary heart disease within the next three years. This initiative aligns with Meijer's commitment to health and wellness, providing accessible cardiovascular care. The partnership between Cardio Diagnostics, FMS, and Meijer aims to offer timely and accurate heart health assessments, especially in rural and suburban regions with healthcare access.
Cardio Diagnostics (NASDAQ: CDIO) will showcase its advanced cardiovascular solutions at the 2024 Onsite Employee Health Clinics Forum in Chicago, IL, from June 27-28, 2024. The event focuses on enabling employers to optimize onsite clinical care facilities. Cardio Diagnostics will highlight its Epi+Gen CHD and PrecisionCHD DNA-based blood tests, which are designed for easy integration into onsite clinics, offering cost savings and reduced absenteeism for employers. The HeartRisk platform will also be featured, providing employers with real-time cardiovascular risk insights. CEO Meesha Dogan expressed enthusiasm about partnering with employers to improve workplace health and productivity.
Cardio Diagnostics Holdings, a leader in AI-driven cardiovascular medicine, has successfully completed its SOC 2 Type I audit. This certification highlights their commitment to data security and confidentiality. Achieving this compliance ensures the company meets stringent security standards set by the AICPA, providing trust for current and future partners. SOC 2 compliance is important in the healthcare sector, safeguarding sensitive patient data from breaches and ensuring adherence to HIPAA regulations. Tim Dogan, CTO, emphasized the importance of maintaining trust and the highest quality and compliance standards.
FAQ
What is the current stock price of Cardio Diagnostics Holdings (CDIO)?
What is the market cap of Cardio Diagnostics Holdings (CDIO)?
